John G Ullman & Associates Inc. Increases Stock Position in Moderna, Inc. (NASDAQ:MRNA)

John G Ullman & Associates Inc. lifted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 341.3% during the third quarter, Holdings Channel reports. The institutional investor owned 49,650 shares of the company’s stock after purchasing an additional 38,400 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Moderna were worth $3,318,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Intrinsic Value Partners LLC increased its holdings in Moderna by 91.1% in the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after buying an additional 24,505 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in Moderna by 11.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after purchasing an additional 167,596 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in Moderna by 148.2% in the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after purchasing an additional 69,313 shares during the last quarter. Profund Advisors LLC increased its position in shares of Moderna by 20.9% in the second quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock valued at $6,676,000 after buying an additional 9,719 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Moderna by 4.2% during the 3rd quarter. Principal Financial Group Inc. now owns 379,451 shares of the company’s stock worth $25,359,000 after buying an additional 15,218 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Ratings Changes

MRNA has been the subject of a number of research reports. Jefferies Financial Group cut their target price on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. Piper Sandler restated an “overweight” rating and set a $69.00 price objective (down from $115.00) on shares of Moderna in a research report on Monday. Leerink Partners lowered their target price on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. JPMorgan Chase & Co. cut their price target on Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a report on Monday, November 4th. Finally, Sanford C. Bernstein began coverage on Moderna in a research note on Thursday, October 17th. They set a “market perform” rating and a $55.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $84.00.

Moderna Stock Down 0.9 %

NASDAQ MRNA opened at $36.94 on Thursday. The company’s fifty day moving average price is $56.98 and its two-hundred day moving average price is $95.46. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the firm earned ($1.39) earnings per share. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. Equities analysts anticipate that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This represents a 13.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 2,930 shares of company stock valued at $217,170. Company insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.